Metronomic Tegafur‐Uracil Maintenance Therapy in Oral Squamous Cell Carcinoma Following Adjuvant Chemoradiotherapy
Oral Diseases · 2026-11-05
DOI: 10.1111/odi.70563 ↗Abstract
ABSTRACT Objective Oral cavity squamous cell carcinoma (OCSCC) is the predominant subtype of head and neck squamous cell carcinoma in Taiwan. Despite the guideline‐recommended adjuvant chemoradiotherapy (CRT) for advanced pathological risk factors, long‐term survival remains suboptimal. We evaluated the efficacy of tegafur‐uracil as metronomic maintenance therapy following adjuvant CRT. Methods This single‐center retrospective cohort study analyzed 197 OCSCC patients who underwent curative resection followed by adjuvant CRT. Patients were stratified by receipt of metronomic tegafur‐uracil maintenance therapy. Survival outcomes were assessed using Cox proportional hazards regression and Kaplan–Meier analyses. Results Patients receiving metronomic maintenance therapy (49.2%, 97/197) demonstrated favorable survival trends compared with those who did not. Five‐year disease‐free survival and disease‐specific survival rates were 57.4% vs. 53.0% ( p = 0.101), and 70.1% versus 60.8% ( p = 0.092), respectively. Patients with ≥ 2 risk factors—extreme body mass index, positive margins, extranodal extension, and advanced depth of invasion—demonstrated significantly better outcomes following metronomic maintenance therapy. Therapy initiation at 1–3 months post‐CRT and a treatment duration exceeding 12 months were also associated with a better prognosis. Conclusion Metronomic tegafur‐uracil maintenance therapy was associated with favorable outcomes, particularly in patients presenting with ≥ 2 identified risk factors. Prospective multicenter validation is warranted.
EUVIMED